Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Blackshear, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blackshear, P. E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Genetically Engineered Rodent Models of Mammary Gland Carcinogenesis: An Overview

Pamela E. Blackshear

Schering-Plough Research Institute, Lafayette, New Jersey 07848, pamela.blackshear{at}spcorp.com

Breast cancer is a multifactorial disease that develops as a result of interactions among genetic, environmental, and hormonal factors. Multiple genetic derangements are believed to be involved in the pathogenesis of breast cancer, including the inactivation of tumor suppressor genes and/or the disregulation of proto-oncogenes. Age, hormones, and environmental factors further influence these genetic derangements. Spontaneous and chemically induced animal models of breast cancer have been limited in their usefulness. The advent of targeted gene mutations has allowed for a more specifi cexploration of the pathogenesis of breast cancer by creating mouse models that mimic single or multiple gene alterations found in human mammary tumors. The genes targeted in these models include mouse mammary tumor integration sites and genes that encode for growth regulators, signal transduction proteins, cell cycle proteins, and cell matrix proteinases. In this review, I summarize tumor morphology and the relevance of each model to the pathogenesis and progression of human breast cancer. These models have great potential for elucidating the multistep process of mammary gland carcinogenesis and for contributing to the identification of novel therapeutic targets.

Key Words: Breast cancer • transgenic models • knockout models • oncogenes • tumor suppressor genes • drug discovery

References

  • Ackler S., Ahmad S., Tobias C., Johnson MD, Glazer RI (2000). The development of mammary hyperplasia in MMTV-AKT1 transgenic mice. Proc Am Assoc Cancer Res 41: 714 (abstract).
  • Adjei AA (2000). Signal transduction pathway target for anticancer drug discovery. Curr Pharm Design 6: 361—378.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Amundadottir LT, Merlino G., Dickson RB (1996). Transgenic mouse models of breast cancer. Breast Cancer Res Treat 39: 119— 135.
  • Andres AC, Schönenberger CA, Groner B., Henninghausen L., LeMeur M., Gerlinger P. (1987). Ha-ras oncogene expression directed by a milk protein gene promoter: Tissue specificity, hormonal regulation, and tumor induction in transgenic mice. Proc Natl Acad Sci USA 84: 1299—1303.[Abstract/Free Full Text]
  • Asch BB (1996). Tumor viruses and endogenous retrotransposons in mammary tumorigenesis. J Mammary Gland Biol Neoplasia 1: 49—60.[CrossRef][Medline] [Order article via Infotrieve]
  • Bartek J., Lukas J., Bartkova J. (1999). Perspective: Defects in cell cycle control and cancer. J Pathol 187: 95—99.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bates P., Fisher R., Ward A., Richardson L., Hill DJ, Graham CF (1995). Mammary cancer in transgenic mice expressing insulin-like growth factor-II (IGF-II). Br J Cancer 72: 1189—1193.[Web of Science][Medline] [Order article via Infotrieve]
  • Bearss DJ, Subler MA, Hundley JE, Troyer DA, Salinas RA, Windle JJ (2000). Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene 19: 1114—1122.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Berg JW (1984). Clinical implications of risk factors for breast cancer. Cancer 53: 589—591.[Medline] [Order article via Infotrieve]
  • Bergstein I., Brown AMC (1999). Wnt genes and breast cancer. In: Molecular Genetics, Pathogenesis, and Therapeutics, Bowcock AM (ed). Humana Press, Totowa, New Jersey, pp 181—198.
  • Bièche I., Laurendau I., Tozlu S., Olivi M., Lidereau R., Vidaud M. (1999). Quantitation of myc gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 59: 2759 — 2765.[Abstract/Free Full Text]
  • Bocchinfuso WP, Hively WP, Couse JF, Varmus HE, Korach KS (1999). A mouse mammary tumor virus-wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-{alpha}. Cancer Res 59: 1869—1876.[Abstract/Free Full Text]
  • Bortner DM, Rosenberg MP (1997). Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 17: 453—459.[Abstract]
  • Bottazzi ME, Assoian RK (1997). The extracellular matrix and mitogenic growth factors control G1 phase cyclins and cyclin-dependent kinase inhibitors. Trends Cell Biol 7: 348—352.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bouchard L., Lamarre L., Tremblay PJ, Jolicoeur P. (1989). Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57: 931—936.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Callahan R. (1996). MMTV-induced mutations in mouse mammary tumors: Their potential relevance to human breast cancer. Breast Cancer Res Treat 39: 33—44.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Callahan R., Smith GH (2000). MMTV-induced mammary tumorigenesis: Gene discovery, progression to malignancy and cellular pathways. Oncogene 19: 992—1001.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cardiff RD, Gumerlock PH, Soong MM, Dandekar S., Barry PA, Young LJ, Meyers FJ (1988). c-H-ras-1 expression in 7,12-dimethyl benzanthracene—induced Balb/c mouse mammary hyperplasia and their tumors. Oncogene 3: 205—213.[Web of Science][Medline] [Order article via Infotrieve]
  • Cardiff RD, Muller WJ (1993). Transgenic mouse models of mammary tumorigenesis. In: The Molecular Pathology of Cancer, Lemoine NR, Wright NA (eds). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp 97—113.
  • Cardiff RD, Wellings SR (1999). The comparative pathology of human and mouse mammary glands. J Mammary Gland Biol Neoplasia 4: 105—122.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cardiff RD, Anver MR, Gusterson BA, Hennighausen L., Jensen RA, Merino MJ, Rehm S., Russo J., Tavassoli FA, Wakefield LM, Ward JM, Green JE (2000). The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting. Oncogene 19: 968—988.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Couch FJ, Deshano ML, Blackwood MA, Calzone K., Stopfer J., Campeau L., Ganguly A., Rerbeck T., Weber BL (1997). BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336: 1409—1415.[Abstract/Free Full Text]
  • Crook T., Brooks L., Crossland S., Osin P., Barker KT, Waller J., Philp E., Smith PD, Yullug I., Peto J., Parker G., Allday MJ, Crompton MR, Gusterson B. (1998). p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1 and BRCA2 associated breast tumours. Oncogene 17: 1681—1689.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Crop CS (1995). Mutations in breast cancer. Cancer Lett 90: 51— 56.
  • Dale TC (1998). Signal transduction by the Wnt family of ligands. Biochem J 329: 209—223.[Web of Science][Medline] [Order article via Infotrieve]
  • Dankort DL, Muller WJ (2000). Signal transduction in mammary tumorigenesis: A transgenic perspective. Oncogene 19: 1038— 1044.
  • Davies BR, Platt-Higgins AM, Schmidt G., Rudland PS (1999). Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGF{alpha} transgenic rats. Am J Pathol 155: 303—314.[Abstract/Free Full Text]
  • Dawe CJ, Freund R., Mandel G., Ballmer-Hofer K., Talmage DA, Benjamin TA (1987). Variations in polyoma virus genotype in relation to tumor induction in mice. Am J Pathol 127: 243—261.[Abstract]
  • deVries JE (1996). p21ras in carcinogenesis. Pathol Res Pract 192: 658—661.[Web of Science][Medline] [Order article via Infotrieve]
  • Dickson C., Creer A., Fantl V. (2000). Mammary gland oncogenes as indicators of pathways important in mammary gland development. Oncogene 19: 1097—1101.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Doetschman T. (1999). Interpretation of phenotype in genetically engineered mice. Lab Anim Sci 49: 137—143.[Web of Science][Medline] [Order article via Infotrieve]
  • Donehower LA, Godley L., Aldaz CM, Pyle R., Shi YP, Pinkel D., Gray J., Bradley A., Medina D., Varmus H. (1995). Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 9: 882—895.[Abstract/Free Full Text]
  • Dow KH (ed) (1996). Contemporary Issues in Breast Cancer. Jones and Bartlett, Sudbury, Massachusetts.
  • Dunnick JK, Elwell MR, Huff J., Barrett JC (1995). Chemically induced mammary gland cancer in the National Toxicology Program's carcinogenesis bioassay. Carcinogenesis 16: 173—179.[Abstract/Free Full Text]
  • Fantl V., Smith R., Brookes S., Dickson C., Peters G. (1993). Chromosome 11q13 abnormalities in human breast cancer. Cancer Surv 18: 77—94.[Web of Science][Medline] [Order article via Infotrieve]
  • Fioravanti L., Cappelletti V., Coradini D., Miodini P., Borsani G., Daidone MG, Di Fronzo G. (1997). int-2 oncogene amplification and prognosis in node-negative breast carcinoma. Int J Cancer 74: 620—624.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fisher GH, Orsulic S., Holland E., Hively WP, Li Y., Lewis BC, Williams BO, Varmus HE (1999). Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene 18: 5253—5260.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Futreal PA, Liu Q., Shattuck-Eidens D., et al (23 coauthors) (1994). BRCA1 mutations in primary breast and ovarian carcinomas. Science 226: 120—122.
  • Giani C., Cullen KJ, Campani D., Rasmussen A. (1996). IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: An in situ hybridization and immunohistochemistry study. Breast Cancer Res Treat 41: 43—50.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Giarré M., Semënov M., Brown AMC (1998). Wnt signaling stabilizes the dual-function protein β-catenin in diverse cell types. Ann NY Acad Sci 857: 43—55.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gibbs JB (2000). Mechanism-based target identification and drug discovery in cancer research. Science 287: 1969—1973.[Abstract/Free Full Text]
  • Goldenberg MM (1999). Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21: 309—318.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Goss PE, Sierra S. (1998). Current perspectives on radiation-induced breast cancer. J Clin Oncol 16: 338—347.[Abstract/Free Full Text]
  • Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH (1996). Brca1 defi ciency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 12: 191 — 194.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Green JE, Shibata MA, Yoshidome K., Liu ML, Jorcyk C., Anver MR, Wigginton J., Wiltrout R., Shibata E., Kaczmarczyk S., Wang W., Liu Z., Calvo A., Couldrey C. (2000). The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: Ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19: 1020 — 1027.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Greenblatt MS, Bennett WP, Hollstein M., Harris CC (1994). Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855—4878.[Free Full Text]
  • Guy CT, Cardiff RD, Muller WJ (1992). Induction of mammary tumors by expression of polyoma middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954 — 961.[Abstract/Free Full Text]
  • Guy CT, Webster MA, Schaller M., Parsons TJ, Cardiff RD, Muller WJ (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578—10582.[Abstract/Free Full Text]
  • Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM (1996). Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 137: 321—330.[Abstract]
  • Hadsell DL (2000). IGF and insulin action in the mammary gland: Lessons from transgenic and knockout models. J Mammary Gland Biol Neoplasia 5: 19—30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hakem R., de la Pompa JL, Sirard C., et al (12 coauthors) (1996). The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85: 1009—1023.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Horak E., Smith K., Bromley L., Lejune S., Greenall M., Lane D., Harris AL (1991). Mutant p53, EGF receptor and c-erbB2 expression in human breast cancer. Oncogene 6: 2277—2284.[Web of Science][Medline] [Order article via Infotrieve]
  • Humphreys RC, Hennighausen L. (2000). Transforming growth factor alpha and mouse models of human breast cancer. Oncogene 19: 1085—1091.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Jacks T., Remington L., Williams BO, Schmitt EM, Halachmi S., Bronson RT, Weinberg RA (1994). Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1—7.[Medline] [Order article via Infotrieve]
  • Jamerson MH, Johnson MD, Dickson RB (2000). Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene 19: 1065—1071.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Jäger R., Herzer U., Schenkel J., Weiher H. (1997). Overexpression of bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc—induced tumorigenesis of the mammary gland in transgenic mice. Oncogene 15: 1787—1795.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Jerry DJ, Kittrell FS, Kuperwasser C., Laucirica R., Dickinson ES, Bonilla PJ, Butel JS, Medina D. (2000). A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene 19: 1052—1058.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kato K., Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ (1992). Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89: 6403—6407.[Abstract/Free Full Text]
  • Knudson AG (1993). Antioncogenes and human cancer. Proc Natl Acad Sci USA 90: 10914—10921.[Abstract/Free Full Text]
  • Koskinen PJ, Alitalo K. (1993). Pole of myc amplification and overexpression in cell growth differentiation, and death. Semin Cancer Biol 4: 3—7.[Medline] [Order article via Infotrieve]
  • Krane IM, Leder P. (1996). NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 12: 1781—1788.[Web of Science][Medline] [Order article via Infotrieve]
  • Kumar R., Medina D., Sukumar S. (1990). Activation of H-ras oncogenes in preneoplastic mouse mammary tissues. Oncogene 5: 1271—1277.[Web of Science][Medline] [Order article via Infotrieve]
  • Kwan H., Pacenka V., Tsukamoto A., Parslow TG, Guzman R., Lin TP, Muller WJ, Lee FS, Leder P. (1992). Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during carcinogenesis in doubly transgenic mice. Mol Cell Biol 12: 147—154.[Abstract/Free Full Text]
  • Lammie GA, Peters G. (1991). Chromosome 11q13 abnormalities in human cancer cells. Cancer Cells 3: 413 — 420.[Web of Science][Medline] [Order article via Infotrieve]
  • Lancaster J., Wooster R., Mangion J., et al (17 coauthors) ( 1996). BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13: 238—240.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Le XF, McWatters A., Wiener J., Wu JY, Mills GB, Bast RC ( 2000). Anti-Her2 antibody and heregulin suppress growth of Her2-overexpressing human breast cancer cells through different mechanism. Clin Cancer Res 6: 260—270.[Abstract/Free Full Text]
  • Lee EYHP (1995). Tumor suppressor genes and their alterations in breast cancer. Semin Cancer Biol 6: 119 — 125.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Levi F., Pasche C., Lucchini F., La Vecchia C. (1996). Alcohol and breast cancer in the Swiss Canton of Vaud. Eur J Cancer 32A: 2108—2113.[CrossRef]
  • Li B., Rosen J., McMenamin-Balano J., Muller WJ, Perkins AS (1997). neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol Cell Biol 17: 3155—3163.[Abstract]
  • Li M., Lewis B., Capuco AV, Laucircia R., Furth PA (2000). WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis. Oncogene 19: 1010—1019.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Li Y., Hively WP, Varmus HE (2000). Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 19: 1002—1009.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Liu CY, Flesken-Nikitin A., Li S., Zeng Y., Lee WH (1996). Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early post-implantation development. Genes Dev 10: 1835—1843.[Abstract/Free Full Text]
  • Lubin F., Wax Y., Modan B. (1986). Role of fat, animal protein, and dietary fiber in breast cancer etiology: A case-control study. J Natl Cancer Inst 77: 605—612.[Web of Science][Medline] [Order article via Infotrieve]
  • Ludwig T., Chapman DL, Papaioannou VE, Efstratiadis A. (1997). Targeted mutations of breast cancer susceptibility genes homologs in mice: Lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/ p53, and Brca2/p53 nullizygous embryos. Genes Dev 11: 1226 — 1241.[Abstract/Free Full Text]
  • Lundgren K., Montes de Oca Luna R., Mcneill YB, Emerick EP, Spencer B., Barfield CR, Lozano G., Rosenberg MP, Finlay CA (1997). Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary development independent of p53. Genes Dev 11: 714 — 725.[Abstract/Free Full Text]
  • Macleod KF, Jacks T. (1999). Insights into cancer from transgenic mouse models. J Pathol 187: 43—60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Malkin D., Li FP, Strong LC, Fraumeni JF, Nelsom CE, Kim DH, Kassel J., Gryka MA, Bischoff FZ, Tainsky MA, Friend SH (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233—1238.[Abstract/Free Full Text]
  • Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA (1998). BRCA1 mutations and breast cancer in the general population. J Am Med Assoc 279: 922—929.[Abstract/Free Full Text]
  • Matsui Y., Halteer SA, Hogan BL, Coffey RJ (1990). Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61: 1147—1155.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McGregor DH, Land CE, Choi K., Tokuooka S., Liu PI, Wakabayashi T., Beebe GW (1977). Breast cancer incidence among atomic bomb survivors, Hiroshima and Nagasaki, 1950—69. J Natl Cancer Inst 59: 799—811.[Web of Science][Medline] [Order article via Infotrieve]
  • McKenzie K., Sukumar S. (1996). Molecular genetics of human breast cancer. In: Cellular and Molecular Mechanisms of Hormonal Carcinogenesis: Environmental Influences, Huff J, Boyd J, Barrett JC (eds). Wiley-Liss, New York, pp 183—209.
  • Miller AB, Howe GR, Sherman GJ, Lindsay JP, Yaffe MJ, Dinner PJ, Risch HA, Prestom DL (1989). Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. N Engl J Med 321: 1285—1289.[Abstract]
  • Muller WJ, Lee FS, Dickson C., Peters G., Pattengale PK, Leder P. (1990). The int-2 gene product acts as an epithelial growth factor in transgenic mice. EMBO J 9: 907—913.[Web of Science][Medline] [Order article via Infotrieve]
  • Nass SJ, Dickson RB (1997). Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat 44: 1—22.[Medline] [Order article via Infotrieve]
  • Nelson AR, Fingleton B., Rothenburg ML, Matrisian LM (2000). Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 18: 1135—1149.[Abstract/Free Full Text]
  • Newman B., Mu H., Butler LM, Millikan RC, Moorman PG, King M. ( 1998). Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. J Am Med Assoc 279: 915—921.[Abstract/Free Full Text]
  • Nielsen LL, Discafani CM, Gurnani M., Tyler RD (1991). Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene. Cancer Res 51: 3762— 3767.
  • Nusse R. (1991). Insertional mutagenesis in mouse mammary tumorigenesis. Curr Top Microbiol Immunol 171: 43—65.[Medline] [Order article via Infotrieve]
  • Paik S. (1992). Expression of IGF-I and IGF-II in breast tissue. Breast Cancer Res Treat 22: 31—38.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Papkoff J., Aikawa M. (1998). Wnt-1 and HGF regulate GSK3β activity and β-catenin signaling in mammary epithelial cells. Biochem Biophys Res Commun 247: 851—858.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Peyrat JP, Bonneterre J., Hecquet B., Vennin P., Louchez MM, Fournier C., Lefebvre J., Demaille A. (1993). Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29A: 492 — 497.[CrossRef]
  • Pravtcheva DD, Wise TL (1998). Metastasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice. J Exp Zool 281: 43—57.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pusztal L. (1993). Growth factors: Regulation of normal and neoplastic growth. J Pathol 169:191—201.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Railo MJ, von Smitten K., Pekonen F. (1994). The prognostic value of insulin-like growth factor-I in breast cancer patients: Results of a follow-up study on 126 patients. Eur J Cancer 30A: 307—311.[CrossRef]
  • Rao GN, Ney E., Herbert RA (1997). Influence of diet on mammary cancer in transgenic mice bearing an oncogene expressed in mammary tissue. Breast Cancer Res Treat 45: 149—158.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Reese DM, Slamon DJ (1997). HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 15: 1—8.[Web of Science][Medline] [Order article via Infotrieve]
  • Rose-Hellekant TA, Sandgren EP (2000). Transforming growth factor alpha— and c-myc—induced mammary carcinogenesis in transgenic mice. Oncogene 19: 1092—1096.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rose DP (1997). Dietary fatty acids and prevention of hormone-responsive cancer. Proc Soc Exp Biol Med 216: 224—233.[CrossRef][Medline] [Order article via Infotrieve]
  • Rosen JM, Humphreys R., Krnacik S., Juo P., Raught B. (1994). The regulation of mammary gland development by hormones, growth factors, and oncogenes. Prog Clin Biol Res 387: 95—111.[Medline] [Order article via Infotrieve]
  • Rowse GJ, Ritland SR, Gendler SJ (1998). Genetic modulation of neu proto-oncogene—induced mammary tumorigenesis. Cancer Res 58: 2675—2679.[Abstract/Free Full Text]
  • Ruan W., Kleinberg DL (1999). Insulin-like growth factor-I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 140: 5075—5081.[Abstract/Free Full Text]
  • Rudolph-Owen LA, Chan R., Muller WJ, Matrisian LM (1998). The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Research 58: 5500—5506.[Abstract/Free Full Text]
  • Rudolph-Owen LA, Matrisian LM (1998). Matrix metalloproteinases in remodeling of the normal and neoplastic mammary gland. Journal of Mammary Gland Biology and Neoplasia 3: 177—189.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Russo J., Gusterson B., Rogers AE, Russo IH, Wellings SR, van Zweiten MJ (1990). Comparative study of human and rat mammary tumorigenesis. Laboratory Investigation 62: 244—278.[Web of Science][Medline] [Order article via Infotrieve]
  • Russo J., Russo IH, Rogers AE, Zwieten MJV, Gusterson B. (1990). Tumours of the mammary gland. In: Pathology of Tumours in Laboratory Animals, Turusov V. and Mohr U. (eds). IARC Scientific Publications, Lyon, France, pp. 47—78.
  • Salomon DS (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Hematol Oncol 19: 183—191.[CrossRef]
  • Sandgren E., Luetteke N., Palmiter R., Brinster R., Lee DC (1990). Overexpression of TGF alpha in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61: 1121—1135.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sandgren EP, Schroeder JA, Qui TH, Palmiter RD, Brinster RL, Lee DC (1995). Inhibition of mammary gland involution is associated with transforming growth factor not c-myc induced tumorigenesis in transgenic mice. Cancer Research 55: 3915—3927.[Abstract/Free Full Text]
  • Sass B., Dunn TB ( 1979). Classification of mouse mammary tumours in Dunn's miscellaneous group including recently reported types. J Natl Cancer Inst 62: 1287—1293.[Web of Science][Medline] [Order article via Infotrieve]
  • Sauer B. (1998). Inducible gene targeting in mice using the Cre/ lox system. Methods 14: 381—392.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schafer WR, Kim R., Sterne R., Thorner J., Kim SH, Rine J. (1989). Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 245: 379—385.[Abstract/Free Full Text]
  • Schönenberger CA, Andres AC, Groner B., van der Valk M., LeMeur M., Gerlinger P. (1988). Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein transcription. EMBO J 7: 169—175.[Web of Science][Medline] [Order article via Infotrieve]
  • Schulze-Garg C., Löhler J., Gocht A., Deppert W. (2000). A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene 19: 1028—1037.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shimizu H., Julius MA, Giarré M., Zheng Z., Brown AMC, Kitajewski J. (1997). Transformation by Wnt family proteins correlates with regulation of β-catenin. Cell Growth Differ 8: 1349—1358.[Abstract]
  • Sinn E., Muller WJ, Pattengale PK, Tepler I., Wallace R., Leder P. (1987). Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 54: 105—115.[CrossRef][Web of Science]
  • Smith CA, Pollice AA, Gu LP, Brown KA, Singh SG, Janocko LE, Johnson R., Julian T., Hyams D., Wolmark N., Sweeney L., Silverman JF, Shackney SE (2000). Correlations among p53, Her/ neu, and ras overexpression and aneuploidy by multiparameter fl ow cytometry in human breast cancer: Evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. Clin Cancer Res 6: 112—126.[Abstract/Free Full Text]
  • Squartini F., Pingitore R. (1994). Tumours of the mammary gland. In: Pathology of Tumours in Laboratory Animals, Turusov V, Mohr U (eds). IARC Scientific Publications, Lyon, France, pp 47— 100.
  • Sternlicht MD, Bissell MJ, Werb Z. (2000). The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 19: 1102—1113.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sternlicht MD, Lochter A., Sympson CJ, Huey B., Rougier JP, Gray JW, Pinkel D., Bissell MJ, Werb Z. (1999). The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell: 137—146.
  • Stewart TA, Pattengale PK, Leder P. (1984). Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MMTV/myc fusion genes. Cell 38: 627—637.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stratton M. (1996). Recent advances in understanding of genetic susceptibility to breast cancer. Hum Mol Genet 5: 1515—1519.[Abstract]
  • Surmacz E. (2000). Function of the IGF-1 receptor in breast cancer. J Mammary Gland Biol Neoplasia 5: 95—105.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Teng DHF, Bogden R., Mitchell JT, et al (15 coauthors) (1996). Low incidence of BRCA mutations in breast carcinoma and other cancers. Nat Genet 13: 241—244.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Thomas DB (1984). Do hormones cause breast cancer? Cancer 53: 595—604.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tsukamoto AS, Grosschedl R., Guzman RC, Parslow T., Varmus HE (1988). Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55: 619—625.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Vomachka A., Pratt SL, Lockefeer J., Horseman ND (2000). Prolactin gene-disruption arrests mammary gland development and retards T-antigen—induced tumor growth. Oncogene 19: 1077— 1084.
  • Vos CBJ, Ter Haar NT, Peterse JL, Cornelisse CJ, van de Vijver MJ (1999). Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J Pathol 187: 279—284.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Walker RA, Varley JM (1993). The molecular pathology of human breast cancer. In: The Molecular Pathology of Cancer, Lemoine NR, Wright NA (eds). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp 31—57.
  • Wang TC, Cardiff RD, Zuckerberg L., Lees E., Arnold A., Schmidt EV (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369: 669—671.[CrossRef][Medline] [Order article via Infotrieve]
  • Watson PH, Pon RT, Shiu RP ( 1991). Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51: 3996 — 4000.[Abstract/Free Full Text]
  • Webster M., Cardiff RD, Muller WJ (1995). Induction of mammary epithelial hyperplasia and mammary tumors in transgenic mice expressing a murine mammary tumor virus activated c-src fusion gene. Proc Natl Acad Sci USA 92: 78849—7853.
  • Welsch CW, Brown CK, Goodrich-Smith M., Van J., Denenberg B., Anderson TM, Brooks CL (1979). Inhibition of mammary tumorigenesis in carcinogen-treated Lewis rats by suppression of prolactin secretion. J Natl Cancer Inst 63: 1211—1214.[Web of Science]
  • Willsher PC, Beaver J., Pinder S., Bell JA, Ellis IO, Blamey RW, Robertson JFR (1996). Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 40: 251—255.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Witty JP, Wright JH, Matrisian LM (1995). Matrix metalloproteinases are expressed during ductal and alveolar mammary morphogenesis, and misregulation of stromelysin-1 in transgenic mice induces unscheduled alveolar development. Mol Cell Biol 6: 1287—1303.
  • Wood TL, Richert MM, Stull MA, Allar MA (2000). The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. JMammary Gland Biol Neoplasia 5: 31—42.[CrossRef]
  • Xu X., Wagner K., Larson D., Weaver Z., Li C., Ried T., Hennighausen L., Wynshaw-Boris A., Deng C. ( 1999). Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22: 37—43.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yee D., Lee AV (2000). Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 5: 107—115.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 29, No. 1, 105-116 (2001)
DOI: 10.1080/019262301301418919
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
K. R. Martin, M. P. Jokinen, H. P. Honeycutt, A. Quinn, F. W. Kari, J. C. Barrett, and J. E. French
Tumor Spectrum in the p53 Heterozygous Zeta Globin-Promoted Tg.AC (v-Ha-ras) Bitransgenic Mouse Model
Toxicol Pathol, June 1, 2004; 32(4): 418 - 425.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Blackshear, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blackshear, P. E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?